Setback in Indian Court Compounds Challenges for Novo Nordisk

Novo Nordisk DK0062498333

Novo Nordisk faces mounting headwinds as a recent legal decision in India deals a blow to its patent strategy. A Delhi court has denied the Danish pharmaceutical giant’s request for an interim injunction against competitor Dr. Reddy’s Laboratories, permitting the continued export of semaglutid. This ruling weakens Novo Nordisk’s patent protection in key markets, arriving during a period of significant pressure on the company’s share price.